These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30148799)

  • 41. Autoantibodies against nuclear, nucleolar, and mitochondrial antigens in systemic sclerosis (scleroderma).
    Reimer G
    Rheum Dis Clin North Am; 1990 Feb; 16(1):169-83. PubMed ID: 2406806
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease.
    Shah AA; Rosen A; Hummers LK; May BJ; Kaushiva A; Roden RBS; Armstrong DK; Wigley FM; Casciola-Rosen L; Visvanathan K
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):71-74. PubMed ID: 28628466
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors.
    Maria ATJ; Partouche L; Goulabchand R; Rivière S; Rozier P; Bourgier C; Le Quellec A; Morel J; Noël D; Guilpain P
    Front Immunol; 2018; 9():3112. PubMed ID: 30687318
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Are endothelial cells stimulated by autoantibodies in scleroderma?
    Nunzi E; Rebora A
    Acta Derm Venereol; 1983; 63(5):458-9. PubMed ID: 6197854
    [No Abstract]   [Full Text] [Related]  

  • 45. Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma.
    Ceribelli A; Cavazzana I; Franceschini F; Airò P; Tincani A; Cattaneo R; Pauley BA; Chan EK; Satoh M
    J Rheumatol; 2010 Oct; 37(10):2071-5. PubMed ID: 20682663
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma.
    Shah AA; Hummers LK; Casciola-Rosen L; Visvanathan K; Rosen A; Wigley FM
    Arthritis Rheumatol; 2015 Apr; 67(4):1053-61. PubMed ID: 25605296
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunologic aspects of scleroderma.
    White B
    Curr Opin Rheumatol; 1994 Nov; 6(6):612-5. PubMed ID: 7865382
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis.
    Baroni SS; Santillo M; Bevilacqua F; Luchetti M; Spadoni T; Mancini M; Fraticelli P; Sambo P; Funaro A; Kazlauskas A; Avvedimento EV; Gabrielli A
    N Engl J Med; 2006 Jun; 354(25):2667-76. PubMed ID: 16790699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis.
    Steen VD; Powell DL; Medsger TA
    Arthritis Rheum; 1988 Feb; 31(2):196-203. PubMed ID: 3348823
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer.
    Betteridge ZE; Priest L; Cooper RG; McHugh NJ; Blackhall F; Lamb JA
    Arthritis Res Ther; 2018 Aug; 20(1):176. PubMed ID: 30092841
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma).
    Senécal JL; Hénault J; Raymond Y
    J Rheumatol; 2005 Sep; 32(9):1643-9. PubMed ID: 16142854
    [No Abstract]   [Full Text] [Related]  

  • 52. Antinuclear antibodies and anti-DNA antibodies in scleroderma. A possible relationship between joint manifestations and increased antibodies in localized scleroderma.
    Serup J; Staun-Olsen P
    Allergy; 1986 Aug; 41(6):452-6. PubMed ID: 3491549
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Autoantibodies in systemic sclerosis.
    Vázquez-Abad D; Rothfield NF
    Int Rev Immunol; 1995; 12(2-4):145-57. PubMed ID: 7650418
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunologic aspects of scleroderma.
    Korn JH
    Curr Opin Rheumatol; 1991 Dec; 3(6):947-52. PubMed ID: 1772749
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Autoantibodies in childhood scleroderma.
    Bernstein RM; Pereira RS; Holden AJ; Black CM; Howard A; Ansell BM
    Ann Rheum Dis; 1985 Aug; 44(8):503-6. PubMed ID: 3875322
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic and immunological differences between Japanese patients with diffuse scleroderma and limited scleroderma.
    Satoh M; Akizuki M; Kuwana M; Mimori T; Yamagata H; Yoshida S; Homma M; Yamamoto T; Sasazuki T
    J Rheumatol; 1994 Jan; 21(1):111-4. PubMed ID: 8151564
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The analysis of antinuclear and antinucleolar autoantibodies of scleroderma by radioimmunoprecipitation assays.
    Kipnis RJ; Craft J; Hardin JA
    Arthritis Rheum; 1990 Sep; 33(9):1431-7. PubMed ID: 2403405
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Undifferentiated Connective Tissue Disease at risk for systemic sclerosis (SSc) (so far referred to as very early/early SSc or pre-SSc).
    Valentini G
    Autoimmun Rev; 2015 Mar; 14(3):210-3. PubMed ID: 25461837
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-topoisomerase I autoantibodies in systemic sclerosis.
    Czömpöly T; Simon D; Czirják L; Németh P
    Autoimmun Rev; 2009 Jul; 8(8):692-6. PubMed ID: 19393194
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiubiquitin antibody in localised and systemic scleroderma.
    Fujimoto M; Sato S; Ihn H; Kikuchi K; Tamaki T; Tamaki K; Takehara K
    Ann Rheum Dis; 1996 Jun; 55(6):399-402. PubMed ID: 8694581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.